Rapid liquid chromatography tandem mass spectrometry determination of rivaroxaban levels in human plasma for therapeutic drug monitoring

Open access

Abstract

A rapid, sensitive, high-throughput liquid chromatography coupled with tandem mass spectrometry method for the quantification of rivaroxaban from human plasma has been developed and validated. For the analytical separation a Zorbax SB-C18 column with isocratic flow of mobile phase composed of 0.2% formic acid in water and acetonitril (65:35, V/V) with a flow rate of 1 mL/min at a temperature of 45ºC was used. Detection of rivaroxaban was performed using positive electrospray ionization and MS/MS mode (sum of m/z 231.1; 289.2 and 318.2 from m/z 436.3). Plasma samples were prepared using single-step protein precipitation with methanol. Method validation was performed with regards to selectivity, linearity (r >0.9927), within-run and between-run precision (CV< 13.1 %) and accuracy (bias< 9.4 %) over a concentration range of 24.00 - 960.00 ng/mL plasma. Recovery was between 96.5 - 108.5% and the lower limit of quantification of rivaroxaban was 24.00 ng/mL. The developed method is simple, rapid, and selective, requires small plasma sample volumes, and was successfully applied for therapeutic drug monitoring of rivaroxaban in treated patients.

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov; 3(11): e442. 2011-30.

2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrium fibrillation. N Engl J Med. 2009 Sep;361(12):1139-51. DOI: 10.1056/NEJMoa0905561

3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrilation. N Engl J Med. 2011 Sep; 365(10):883-91. DOI: 10.1056/NEJMoa1009638

4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep; 365(11):981-92. DOI: 10.1056/NEJMoa1107039

5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov; 369(22):2093-104. DOI: 10.1056/ NEJMoa1310907

6. Scridon A, Șerban RC. Laboratory monitoring - a turning point in the use of new oral anticoagulants. Ther Drug Monit. 2016 Feb; 38(1):12-21. DOI: 10.1097/ FTD.0000000000000247

7. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2013 Jan;11:756-60. DOI: 10.1111/jth.12149

8. Kuhn J, Gripp T, Flieder T, Dittrich M, Hendig D, Busse J, et al. UPLC-MRM mass spectrometry method for measurement of the coagulation inhibitors dabigatran and rivaroxaban in human plasma and its comparison with functional assays. PLoS ONE. 2015 Dec; 10(12):e0145478. DOI: 10.1371/journal.pone.0145478

9. Korostelev M, Bihan K, Ferreol L, Tissot N, Hulot JS, Funck-Brentano C, et al. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2014 Nov;100:230-5. DOI: 10.1016/j.jpba.2014.08.011

10. Cheng YH, Chen WC, Chang SY. Rapid determination of rivaroxaban in human urine and serum using colloidal palladium surface-assisted laser desorption/ ionization mass spectrometry. Rapid Commun Mass Spectrom. 2015 Nov; 29(21):1977-83. DOI: 10.1002/ rcm.7308

11. Rohde G. Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep; 872(1-2):43-50. DOI: 10.1016/j. jchromb.2008.07.015

12. Schellings MW, Boonen K, Schmitz EM, Jonkers F, van den Heuvel DJ, Besselaar A, et al. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. Thromb Res. 2016 Mar; 139:128-34. DOI: 10.1016/j. thromres.2016.01.012

13. Srinivas Reddy G, Prasad Reddy SLN, Shiva Kumar Reddy L. Development and validation of Hplc-Ms/Ms Method for Rivaroxaban quantitation in human plasma using solid phase extraction procedure. Orient J Chem. 2016 Dec; 32(2):1145-54. DOI: 10.13005/ojc/320240

14. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Veterinary Medicine (CVM). Guidance for Industry. Bioanalytical Method Validation. 2013 Sep; available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf

15. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation. 2011, Jul; available at http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf

16. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008 Jan; 47(1):47-59. DOI: 10.2165/00003088-200847010-00005

17. EINSTEIN-PE Investigators, Bűller HR, Prins MH, Lensin AW, Decousus H, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr; 366(14):1287-97. DOI: 10.1056/NEJMoa1113572

18. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral direct factor Xa inhibitor. Nat Rev Drug Discov. 2011 Jan;10(1):61-75. DOI: 10.1038/nrd3185

19. Gnoth MJ, Buetehorn U, Muenster U, Schwartz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther. 2011 Jul;338(1):372-80. DOI: 10.1124/ jpet.111.180240

20. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther. 2007 Jun; 45(6):335-44. DOI: 10.5414/CPP45335

21. Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J 2013 Jun; 11(1):8. DOI: 10.1186/1477-9560-11-8

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information


IMPACT FACTOR 2018: 0,800
5-year IMPACT FACTOR: 0,655



CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2018: 0.194
Source Normalized Impact per Paper (SNIP) 2018: 0.306

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 395 313 40
PDF Downloads 180 147 9